<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066945</url>
  </required_header>
  <id_info>
    <org_study_id>202103748</org_study_id>
    <nct_id>NCT05066945</nct_id>
  </id_info>
  <brief_title>Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients</brief_title>
  <official_title>Application of Circulating Tumor (ctDNA) in the Evaluation of Curative Effect and Prognosis of Small Cell Lung Cancer (SCLC) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the application value of circulating tumor&#xD;
      DNA(ctDNA) with efficacy evaluation and prognostic assessment in patients with unresectable&#xD;
      SCLC, who were receiving radiotherapy and chemotherapy treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. According to each point in time of ctDNA, to analyze the dynamic changes of tumor burden&#xD;
           and clonal subtypes which to evaluate the application value of ctDNA in curative&#xD;
           efficacy evaluation.&#xD;
&#xD;
        2. Compare the two time points before and after radiotherapy and chemotherapy treatment of&#xD;
           the cell free DNA (cfDNA) concentration and tumor burden, analysis the correlation&#xD;
           between the changes and prognosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ctDNA mutation profile at baseline</measure>
    <time_frame>before treatment ctDNA mutation analysis and clonal analysis (each cycle is 3 weeks)</time_frame>
    <description>ctDNA mutation will be detected, PyClone based clonal analysis will be performed to analyze the clonal dominance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the evolution of ctDNA mutation profile during treatment</measure>
    <time_frame>After the first cycle of first line treatment upon physicians' request, ctDNA mutation analysis and clonal analysis (each cycle is 3 weeks)</time_frame>
    <description>ctDNA mutation will be detected, PyClone based clonal analysis will be performed to analyze the clonal dominance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the evolution of ctDNA mutation profile during treatment</measure>
    <time_frame>After finished the first line treatment, ctDNA mutation analysis and clonal analysis (each cycle is 3 weeks)</time_frame>
    <description>ctDNA mutation will be detected, PyClone based clonal analysis will be performed to analyze the clonal dominance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From the first line treatment to the time of disease progression (through study completion, an average of 5 months)</time_frame>
    <description>Progression free of survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Small Cell Lung Cancer Extensive Stage</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>observe the association of ctDNA with efficacy of treatment</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        treatment extensive stage small cell lung cancer patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consentï¼›&#xD;
&#xD;
          -  Newly diagnosed and histological or cytological confirmed extensive stage small cell&#xD;
             lung cancer;&#xD;
&#xD;
          -  All indicators has confirmed and allow to receive radiotherapy and chemotherapy;&#xD;
&#xD;
          -  Follow-up can be carried out and the peripheral blood samples can be collected;&#xD;
&#xD;
          -  Cooperate with the provision of clinical pathological data required by the research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients have other primary cancers;&#xD;
&#xD;
          -  Patients unable to cooperate with the study for follow-up according to the determined&#xD;
             clinical follow-up cycle;&#xD;
&#xD;
          -  Unable to accept the judgment of curative effect evaluation by the designated methods&#xD;
             such as CT.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Deng</last_name>
    <phone>13574888840</phone>
    <email>yogurt1015@csu.edu.cn</email>
  </overall_contact>
  <reference>
    <citation>Mohan S, Foy V, Ayub M, Leong HS, Schofield P, Sahoo S, Descamps T, Kilerci B, Smith NK, Carter M, Priest L, Zhou C, Carr TH, Miller C, Faivre-Finn C, Blackhall F, Rothwell DG, Dive C, Brady G. Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC. J Thorac Oncol. 2020 Feb;15(2):216-230. doi: 10.1016/j.jtho.2019.10.007. Epub 2019 Oct 16.</citation>
    <PMID>31629061</PMID>
  </reference>
  <reference>
    <citation>Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Chen M, Byers L, Roarty E, Lam VK, Papadimitrakopoulou VA, Wistuba I, Heymach JV, Glisson B, Liao Z, Lee JJ, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun. 2018 Aug 6;9(1):3114. doi: 10.1038/s41467-018-05327-w. Erratum in: Nat Commun. 2019 Jan 29;10(1):552.</citation>
    <PMID>30082701</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>dengpengbo</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD data for publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>IPD will be shared when the clinical trail is completed.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

